Applied Genomic Technology Capital Funds Close with $150M in Capital | GenomeWeb

NEW YORK, March 5 – With $150 million in capital commitments, Applied Genomic Technology Capital Funds has closed its first venture funds, the Cambridge, Mass., venture capital group said Monday.

AGTC Funds, which was founded by venture capital firms NewcoGen and OneLiberty Ventures, plans to finance early-stage genomics companies that focus on information, discoveries, and technology. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.